The Supreme Court ruled 6-3 against President Trump’s use of emergency powers to impose tariffs, impacting drug imports. This decision affects hospital leaders and pharmaceutical manufacturers relying on global supply chains. The ruling limits the administration’s use of the International Emergency Economic Powers Act, which was previously leveraged to impose tariffs. The immediate consequence is a potential shift in drug import strategies as stakeholders assess the ruling’s implications on supply chain operations and costs.
